SCHEMBL17165877

SCHEMBL17165877

CCN1C(=O)C(=O)c2ccc(Br)c(C)c21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 4/20 0.49
PARK7 Q99497 4/20 0.44
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
ACHE P22303 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CASP3 P42574 1/20 0.38
CASP7 P55210 1/20 0.38
POLB P06746 1/20 0.37
CUL4A Q13619 1/20 0.37
CES1 P23141 2/20 0.36
BCHE P06276 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25756589 0.80 CYP1B1 (0.46) CYP1B1PARK7MAPTTP53ALDH1A1
SCHEMBL17165873 0.76 PARK7 (0.44) CYP1B1PARK7MAPTTP53ACHE
SCHEMBL19630025 0.75 PARK7 (0.50) CYP1B1PARK7MAPTTP53ACHE
SCHEMBL7243578 0.75 CTRB1 (0.49) CYP1B1PARK7MAPTTP53ACHE
SCHEMBL7244266 0.73 PARK7 (0.50) PARK7MAPTTP53ACHEALDH1A1
SCHEMBL28026697 0.71 PARK7 (0.53) CYP1B1PARK7MAPTACHEALDH1A1
SCHEMBL31003772 0.71 PARK7 (0.53) CYP1B1PARK7MAPTALDH1A1HTT
SCHEMBL17165976 0.71 DRD2 (0.35) CYP1B1PARK7TP53ALDH1A1HTT
SCHEMBL31528311 0.69 CHRM5 (0.42) CYP1B1PARK7MAPTTP53ALDH1A1
SCHEMBL22667286 0.68 CUL4A (0.68) PARK7MAPTACHEALDH1A1CUL4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10385065-B2 Antibacterial compounds REDX PHARMA PLC (GB) 2019-08-20 US disclosed
US-10385065-B2 Antibacterial compounds REDX PHARMA PLC (GB) 2019-08-20 US disclosed
US-20170158708-A1 ANTIBACTERIAL COMPOUNDS REDX PHARMA PLC (GB) 2017-06-08 US disclosed
US-20170158708-A1 ANTIBACTERIAL COMPOUNDS REDX PHARMA PLC (GB) 2017-06-08 US disclosed
US-20170158708-A1 ANTIBACTERIAL COMPOUNDS REDX PHARMA PLC (GB) 2017-06-08 US disclosed
WO-2017046603-A1 ANTIBACTERIAL COMPOUNDS AND NEW USES THEREOF REDX PHARMA PLC (GB) 2017-03-23 WO disclosed
EP-3129386-A1 ANTIBACTERIAL COMPOUNDS Redx Pharma PLC (GB) 2017-02-15 EP disclosed
WO-2015155549-A1 ANTIBACTERIAL COMPOUNDS REDX PHARMA PLC (GB) 2015-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158708-A1 ANTIBACTERIAL COMPOUNDS ABCC1, SLC11A2, NQO2 CYP1B1 1046/4885PARK7 2131/4885MAPT 2265/4885
US-10385065-B2 Antibacterial compounds ABCC1, SLC11A2, NQO2 CYP1B1 1046/4885PARK7 2131/4885MAPT 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.